Green Cross have published a series of biarylpyrazolyl oxadiazole based compounds as CB1 antagonists
Filed under: Uncategorized | Tagged: antagonist, Cannabinoid, Cannabinoid CB1, CB1, Green Cross | Leave a Comment »
Jenrin’s CB1 antagonists show efficacy with less adverse effects
Posted on November 1, 2008 by crimsoncanary
Data presented at the Annual Scientific Meeting of the Obesity Society show Jenrin’s CB1 antagonist are capable of having a metabolic effect while reducing risks of psychiatric side effects.
Filed under: Uncategorized | Tagged: antagonist, cannabin, Cannabinoid CB1, CB1, jenrin | Leave a Comment »
Merck discontinue development of CB-1 agonist taranabant
Posted on October 2, 2008 by crimsoncanary
Merck has discontinued dvelopment of Cannabinoid 1 agonist Taranabant for Obesity due to adverse events
Filed under: Uncategorized | Tagged: Cannabinoid CB1, CB-1, CB1, Merck, taranabant | Leave a Comment »
KeyNeurotek receive EMEA Orphan Drug Designation for KN38-7271 in TBI
Posted on September 22, 2008 by crimsoncanary
KeyNeurotek Pharmaceuticals have received Orphan Drug Designation for its lead cannabinoid agonist compound KN38-7271 for the treatment of moderate and severe closed traumatic brain injury from EMEA
Filed under: Uncategorized | Tagged: Cannabinoid, Cannabinoid CB1, Cannabinoid CB2, CB1, CB2, regulatory | Leave a Comment »
Watson Launch Generic Dronabinol
Posted on June 30, 2008 by crimsoncanary
Watson have announced the launch of generic dronabinol under a supply agreement with Solvay Pharmaceuticals.
Filed under: gpcr | Tagged: Cannabinoid, Cannabinoid CB1, CB!, CB1, Compassia, delta-9-THC, Dronabinol, Elevat, Generic, Marinol, Solvay, watson | Leave a Comment »
Pfizer to initiate Phase 1 Study Of CP-945598 In Patients With NASH
Posted on June 27, 2008 by crimsoncanary
Pfizer are about to begin a Phase I study of Cannabinoid 1 antagonist CP-945598 In Patients With Nonalcoholic steatohepatitis (NASH)
Filed under: Uncategorized | Tagged: antagonist, Cannabinoid, CB1, CP-945598, CP945598, Pfizer, phase I | Leave a Comment »
Rimonabant effective in Type 2 Diabetes
Posted on June 11, 2008 by crimsoncanary
Clinical data presented at ADA show Sanofi-aventis’ CB1 antagonist rimonabant significantly improved glucose levels (as measured by HbA1c) compared to controls in patients with type 2 diabetes
Filed under: gpcr | Tagged: Acomplia, antagonist, Cannabinoid, CB1, Rimonabant, Sanofi-Aventis, Slimona, SR-141716, SR-141716A, SR141716, SR141716A, Zimulti | Leave a Comment »
